This article is more than 5 years old. Information may no longer be current.
PHiD-CV10 vaccine slightly reduces use of tubes for ear infections
Click Here to Manage Email Alerts
Pneumococcal Haemophilus influenzae protein D conjugate vaccine had a slight effect on the amount of tympanostomy tube placement procedures, a treatment for otitis media, resulting in fewer placement procedures, according to a recent study.
“The potential reduction in this health burden reported here contributes to the public health benefit of pneumococcal conjugate vaccinations,” Arto A. Palmu, MD, PhD, of the department of vaccination and immune protection at the National Institute for Health and Welfare, Finland, and colleagues wrote. “The major morbidity due to otitis media results in extensive use of health care resources including high number of tympanostomy tube placement procedures.”
As part of the Finnish Invasive Pneumococcal (FinIP) disease vaccine trial, 47,366 children aged younger than 19 months were administered pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10, GlaxoSmithKline) as part of the variable group, or a hepatitis vaccine as part of the control group.
Results showed that the reduction in cases of tympanostomy tube placements was 1.1 per 100 person-years (95% CI, –0.2 to 2.5), with 7.9 recorded in the control group and 6.8 recorded in the variable group. The researchers noted that although this difference was not statistically significant, results indicated that PHiD-CV10 administered before patients were aged 12 months may reduce the frequency of tympanostomy tube placement procedures.
“Children most prone to otitis media are usually affected during their first year of life and administration of vaccinations after this may not reverse the burden instantly,” Palmu and colleagues wrote. “However, we observed a considerable vaccine impact in this cohort during the longer term follow-up, when up to half of the procedures were recurrent procedures of children with at least one previous procedure.” – by David Costill
Disclosure: The FinIP trial was funded by GlaxoSmithKline Biologicals. Palmu reports receiving travel funding and honoraria from GlaxoSmithKline and travel funding from Merck. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts